Related Experiment Videos
[Radiotherapy of hematologic diseases]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|April 15, 1976
Summary
Radiotherapy offers survival benefits for undifferentiated cell leukoses and improves remission rates in chronic leukoses. It is a key treatment for lymphogranulomatosis and polycythemia vera, with palliative roles in myeloma.
Area of Science:
- Oncology
- Radiation Oncology
Context:
- Radiotherapy's role in hematologic malignancies.
- Evolving treatment paradigms in cancer therapy.
Purpose:
- To survey the possibilities and limitations of radiotherapy across various leukoses and related cancers.
- To evaluate radiotherapy's efficacy in improving survival and remission rates.
Summary:
- Radiotherapy enhances 5-year survival in central nervous system involvement of undifferentiated cell leukoses due to poor drug penetration.
- For chronic leukoses, spleen irradiation and lymph node treatment offer palliative benefits and improved remission rates.
- Lymphogranulomatosis treatment involves radiotherapy with or without chemotherapy, achieving high cure rates in early stages.
- Radiotherapy, particularly radioactive phosphorus incorporation, is the primary treatment for polycythemia vera and plays a palliative role in myeloma.
Impact:
- Highlights radiotherapy's established and potential benefits in managing specific hematologic cancers.
- Informs clinical decision-making regarding radiotherapy indications and its integration with systemic therapies.
- Underscores the importance of tailored radiotherapy approaches based on disease type, stage, and patient factors.